TENAX THERAPEUTICS INC

Tenax Therapeutics’ latest 7.98% rally masks weak fundamentals—low market cap, steep decline, and no product pipeline—highlighting a potential speculative bubble.

Tenax Therapeutics stock flat at $1.69; ADAR1 Capital builds stake in its pulmonary hypertension drug pipeline – latest equity move & market recap.

Tenax Therapeutics shares climb 7.24% as the biotech firm advances pulmonary hypertension treatments, now trading near $1.63.

Tenax Therapeutics (TENX) surged 11.8% to $1.63, outpacing peers. Discover why the biotech firm’s pulmonary hypertension focus fuels its rising market cap.